Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian T Ruff

Showing results (11-20 of 192) with videos related to

Pageof 20
Sort By:
Circulation|March 25, 2024
Subclinical Atrial Fibrillation and Anticoagulation: Weighing the Absolute Risks and BenefitsSiddharth M Patel, Christian T Ruff
Circulation|July 28, 2025
Probing the Proteome for Atrial FibrillationSiddharth M Patel, Christian T Ruff
Current Cardiology Reports|July 23, 2024
Will Factor XI Inhibitors Replace Current Anticoagulants for Stroke Prevention in Atrial Fibrillation?Siddharth M Patel, Christian T Ruff
Future Cardiology|October 7, 2009
Inhibition of tissue factor as a novel approach to anticoagulation in patients with coronary artery diseaseChristian T Ruff, Robert Giugliano, David A Morrow
Hematology/Oncology Clinics of North America|September 18, 2016
Non-Vitamin K Antagonist Oral Anticoagulants in Atrial FibrillationAnna Plitt, Christian T Ruff, Robert P Giugliano
The New England Journal of Medicine|April 16, 2025
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. ReplyChristian T Ruff, Erica L Goodrich, Marc S Sabatine
Chest|June 9, 2019
ResponseGregory Y H Lip, Christian T Ruff, Lisa Moores, et al.
Circulation|July 21, 2016
Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal AgentsChristian T Ruff, Robert P Giugliano, Elliott M Antman
Clinical Chemistry|December 14, 2020
Biomarkers for Risk Assessment in Atrial FibrillationDavid D Berg, Christian T Ruff, David A Morrow
Chest|June 9, 2019
ResponseGregory Y H Lip, Christian T Ruff, Lisa Moores, et al.
Pageof 20

Showing results (11-20 of 192) with videos related to

Sort By:
Pageof 20
Circulation|March 25, 2024
Subclinical Atrial Fibrillation and Anticoagulation: Weighing the Absolute Risks and BenefitsSiddharth M Patel, Christian T Ruff
Circulation|July 28, 2025
Probing the Proteome for Atrial FibrillationSiddharth M Patel, Christian T Ruff
Current Cardiology Reports|July 23, 2024
Will Factor XI Inhibitors Replace Current Anticoagulants for Stroke Prevention in Atrial Fibrillation?Siddharth M Patel, Christian T Ruff
Future Cardiology|October 7, 2009
Inhibition of tissue factor as a novel approach to anticoagulation in patients with coronary artery diseaseChristian T Ruff, Robert Giugliano, David A Morrow
Hematology/Oncology Clinics of North America|September 18, 2016
Non-Vitamin K Antagonist Oral Anticoagulants in Atrial FibrillationAnna Plitt, Christian T Ruff, Robert P Giugliano
The New England Journal of Medicine|April 16, 2025
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. ReplyChristian T Ruff, Erica L Goodrich, Marc S Sabatine
Chest|June 9, 2019
ResponseGregory Y H Lip, Christian T Ruff, Lisa Moores, et al.
Circulation|July 21, 2016
Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal AgentsChristian T Ruff, Robert P Giugliano, Elliott M Antman
Clinical Chemistry|December 14, 2020
Biomarkers for Risk Assessment in Atrial FibrillationDavid D Berg, Christian T Ruff, David A Morrow
Chest|June 9, 2019
ResponseGregory Y H Lip, Christian T Ruff, Lisa Moores, et al.
Pageof 20